	US 12,233,088 B2
	Bis-choline tetrathiomolybdate for treating Wilson Disease
Carl Bjartmar, Stockholm (SE); Karl-Heinz Weiss, Stockholm (SE); Michael Schilsky, Stockholm (SE); Frederick Askari, Stockholm (SE); Anna Czlonkowska, Stockholm (SE); Peter Ferenci, Stockholm (SE); Peter Hedera, Stockholm (SE); and Aftab Ala, Stockholm (SE)
Assigned to Alexion Pharmaceutical, Inc., Boston, MA (US)
Filed by Alexion Pharmaceuticals, Inc., Boston, MA (US)
Filed on Aug. 23, 2022, as Appl. No. 17/821,786.
Application 17/821,786 is a continuation of application No. 16/997,928, filed on Aug. 19, 2020, granted, now 11,419,832, issued on Aug. 23, 2022.
Application 17/821,786 is a continuation of application No. 16/770,022, granted, now 11,510,944, previously published as PCT/EP2018/083551, filed on Dec. 4, 2018.
Claims priority of provisional application 62/750,595, filed on Oct. 25, 2018.
Claims priority of provisional application 62/741,313, filed on Oct. 4, 2018.
Claims priority of provisional application 62/669,095, filed on May 9, 2018.
Claims priority of provisional application 62/655,568, filed on Apr. 10, 2018.
Claims priority of provisional application 62/646,553, filed on Mar. 22, 2018.
Claims priority of provisional application 62/594,184, filed on Dec. 4, 2017.
Prior Publication US 2023/0070534 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/24 (2019.01); A61K 9/00 (2006.01); A61K 9/28 (2006.01); A61K 31/14 (2006.01); A61P 3/00 (2006.01)

CPC A61K 33/24 (2013.01) [A61K 9/0053 (2013.01); A61K 9/28 (2013.01); A61K 31/14 (2013.01); A61P 3/00 (2018.01)]

17 Claims

1. A method of treating Wilson Disease in a patient, comprising administering bis-choline tetrathiomolybdate to the patient in need thereof in a fasted state.